Apnimed key facts
as of Oct 2026- Developer of a pharmacologic therapy designed to target orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction.
- Apnimed is valued at approximately $434.0M as of Oct 2026, set at its later-stage round, Mar 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $434.3M across 8 recorded rounds; the latest was Early Stage VC ($25.0M) in Mar 2026.
- Notable investors include Alpha Wave Global, Morningside Group, Tao Capital Partners, Columbia Seligman, NexPoint (Asset Management) — 7 tracked in total.
- Apnimed has filed 15 Form Ds with the SEC since 2018, most recently Mar 2026 ($25.0M sold to 2 investors).
- Status: Privately Held (backing).
Valued at $434.0M at its later-stage round, Mar 2026. Nothing has traded since.
- ·Watch Apnimed: the Monday email on marks, rounds and moves
Apnimed funding rounds
8 roundsApnimed valuation
Apnimed was valued at $434 million at its later-stage round in Mar 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Apnimed raised?
Apnimed has raised $434 million across 8 recorded rounds since 2018. The largest was a $79.7 million later-stage round in Dec 2022; the most recent was a $25 million early-stage round in Mar 2026.
Apnimed has filed 15 Form Ds with the SEC since 2018, most recently in Mar 2026 ($25 million sold to 2 investors).
Apnimed investors
7 investors are on record for Apnimed, including Alpha Wave Global, Morningside Group, Tao Capital Partners and Columbia Seligman. The early-stage round in Mar 2026 drew 2 investors.
About Apnimed
Developer of a pharmacologic therapy designed to target orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction. The company's therapeutics address the physiologic and symptomatic effects of obstructive sleep apnea, providing patients with a safe and effective treatment that addresses the underlying biology of the disease.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 78
- Website
- apnimed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.